Sponsor content
70 result(s) found, displaying 31 to 40
-
Prescription medicine registrationActive ingredients: Ustekinumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VEGZELMA bevacizumab 400 mg/ 16 mL solution for intravenous infusion, vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VEGZELMA bevacizumab 100 mg/ 4 mL solution for intravenous infusion, vial.
-
YUFLYMA adalimumab 80 mg/0.8 mL solution for injection pre-filled syringe with safety guard (396991)
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab 80 mg/0.8 mL solution for injection pre-filled syringe with safety guard. -
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab 80 mg/0.8 mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab 80 mg/0.8 mL solution for injection pre-filled syringe in auto injector pen.
-
Australian public assessment report (AusPar)Vegzelma (bevacizumab), in combination with fluoropyrimidine-based chemotherapy, has been approved for the treatment of metastatic colorectal cancer.
-
Prescription medicine registrationActive ingredients: Bevacizumab.
-
EMISIMA infliximab (rmc) 100mg Powder for Injection vial Cancelled under Section 30(1)(c) of the Act
Cancellation by sponsorRequested by Celltrion Healthcare Australia Pty Ltd -
Cancellation by sponsorRequested by Celltrion Healthcare Australia Pty Ltd